blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3177327

EP3177327 - INHIBITORS OF MYH7B AND USES THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  10.05.2021
Database last updated on 30.09.2024
FormerGrant of patent is intended
Status updated on  03.08.2020
FormerExamination is in progress
Status updated on  08.03.2019
FormerRequest for examination was made
Status updated on  12.05.2017
FormerThe international publication has been made
Status updated on  03.03.2017
Most recent event   Tooltip10.05.2021Application deemed to be withdrawnpublished on 09.06.2021  [2021/23]
Applicant(s)For all designated states
Miragen Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301 / US
[2017/24]
Inventor(s)01 / MONTGOMERY, Rusty
6200 Lookout Road
Boulder, Colorado 80301 / US
02 / DALBY, Christina
6200 Lookout Road
Boulder, Colorado 80301 / US
 [2017/24]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[N/P]
Former [2017/24]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Application number, filing date15829559.204.08.2015
[2017/24]
WO2015US43571
Priority number, dateUS201462033018P04.08.2014         Original published format: US 201462033018 P
[2017/24]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016022536
Date:11.02.2016
Language:EN
[2016/06]
Type: A2 Application without search report 
No.:EP3177327
Date:14.06.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 11.02.2016 takes the place of the publication of the European patent application.
[2017/24]
Search report(s)International search report - published on:US31.03.2016
(Supplementary) European search report - dispatched on:EP13.02.2018
ClassificationIPC:C12N15/113, A61K31/712
[2018/11]
CPC:
C12N15/113 (EP,KR,US); A61K31/7105 (EP,KR,US); A61K31/713 (EP,KR,US);
A61K45/06 (EP,KR,US); A61P9/00 (EP); A61P9/04 (EP);
A61P9/10 (EP); A61K2300/00 (KR,US); C12N2310/11 (EP,US);
C12N2310/315 (EP,US); C12N2310/321 (KR,US); C12N2310/322 (US);
C12N2310/3231 (EP,US); C12N2310/3341 (EP,US); C12N2310/341 (EP,US);
C12N2310/346 (EP,US); C12N2310/3521 (KR) (-)
C-Set:
A61K31/7105, A61K2300/00 (US,EP);
A61K31/713, A61K2300/00 (EP,US);
C12N2310/321, C12N2310/3521 (US,EP)
Former IPC [2017/24]A61K48/00, C07H21/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/24]
TitleGerman:INHIBITOREN VON MYH7B UND VERWENDUNGEN DAVON[2017/24]
English:INHIBITORS OF MYH7B AND USES THEREOF[2017/24]
French:INHIBITEURS DE MYH7B ET UTILISATIONS ASSOCIÉES[2017/24]
Entry into regional phase02.03.2017National basic fee paid 
02.03.2017Search fee paid 
02.03.2017Designation fee(s) paid 
02.03.2017Examination fee paid 
Examination procedure02.03.2017Examination requested  [2017/24]
02.03.2017Date on which the examining division has become responsible
12.09.2018Amendment by applicant (claims and/or description)
13.03.2019Despatch of a communication from the examining division (Time limit: M04)
23.07.2019Reply to a communication from the examining division
22.11.2019Despatch of a communication from the examining division (Time limit: M06)
27.05.2020Reply to a communication from the examining division
04.08.2020Communication of intention to grant the patent
15.12.2020Application deemed to be withdrawn, date of legal effect  [2021/23]
22.01.2021Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2021/23]
Fees paidRenewal fee
14.08.2017Renewal fee patent year 03
10.08.2018Renewal fee patent year 04
15.08.2019Renewal fee patent year 05
13.08.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2007042982  (BENTWICH ITZHAK [IL]) [X] 1 * sequence 47581 *;
 [X]WO2013173601  (RANA THERAPEUTICS INC [US], et al) [X] 1 * sequence 38094 *;
 [I]  - RUSTY L MONTGOMERY ET AL, "Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure", vol. 124, no. 14, doi:10.1161/CIRCULATIONAHA.111.030932, ISSN 1524-4539, (20110101), pages 1537 - 1547, 1, CIRCULATION, AMERICAN HEART ASSOCIATION, INC, & SCIENTIFIC SESSIONS OF THE AMERICAN-HEART-ASSOCIATION / RESUSCITATION SCIENCE SYMPOSIUM; NEW ORLEANS, LA, USA; NOVEMBER 12 -16, 2016, URL: http://circ.ahajournals.org/content/124/14/1537, (20110906), XP002674571 [I] 1,7 * the whole document *

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.111.030932
    [ ] - "Human bioinformatically detectable RNA oligonucleotide SEQ ID 47581.", Geneseq, (20081030), Database accession no. ASP65840, URL: EBI, XP055448270 [ ] * the whole document *
    [ ] - "Human BDNF oligonucleotide, SEQ:38094.", Geneseq, (20140116), Database accession no. BBA06210, URL: EBI, XP055448273 [ ] * the whole document *
International search[A]US2005255487  (KHVOROVA ANASTASIA [US], et al) [A] 2, 3, 5, 22, 23, (24-25)/(2, 3, 5, 22, 23)* SEQ ID NO: 1672865 (SEQ ID NO: 2269522, SEQ ID NO:2269583, SEQ ID NO: 2533158, SEQ ID NO: 2643889), nucleotides 19-6 *;
 [YA]WO2012140234  (VIB VZW [BE], et al) [Y] 24/1 * claims 2, 3, pg 24 * [A] 25/1;
 [XYA]US2013331433  (THIBONNIER MARC [US]) [X] 1 * pg 35, Table 8, hsa-miR-1443p * [Y] 7-16, 18-20, 24/(1, 7-16, 18-20) [A] 2, 3, 5, 22, 23, 24/(2, 3, 5, 22, 23), 25;
 [YA]US2013344135  (VAN ROOIJ EVA [NL], et al) [Y] 7-16, 18-20, 24/(7-16, 18-20) * claims 1, 6-9, 14, 29-31; para [0007]-[0010] * [A] 25/(7-16, 18-20);
 [A]  - "Homo sapiens myosin, heavy chain 7B, cardiac muscle, beta (MYH7B), mRNA", NCBI, (20140621), Database accession no. NM_020884.4 [A] 1-3, 5, 7-16, 18-20, 22-25 * ; in entirety *
 [YA]  - HU et al., "An Agomir of miR-144-3p Accelerates Plaque Formation through Impairing Reverse Cholesterol Transport and Promoting Pro-Inflammatory Cytokine Production.", PLoS ONE, (20140414), vol. 9, no. 4, page e94997, XP055395095 [Y] 7-16, 18-20, 24/(7-16, 18-20) * ; Abstract * [A] 25/(7-16, 18-20)

DOI:   http://dx.doi.org/10.1371/journal.pone.0094997
by applicantUS5270163
 US5783565
 US5837533
 US5981505
 US6127170
 US6217900
 US6379965
 US6383512
 US6403566
 US6416510
 US6589286
 WO03093449
 WO2004004602
 US6693187
 US6716196
 US6716242
 US6747014
 US6838283
 WO2005082440
 US6953466
 US7041127
 US7055237
 US7067641
 US2006148742
 US7083642
 US7087263
 WO2006089340
 US7105018
 US7144422
 US7156869
 US2007060907
 US7202227
 US7232573
 US7236821
 US7247313
 US2007203445
 US7273493
 US7294329
 US2009264508
 US2011076322
 WO2012083005
 WO2013192486
    - TEEKAKIRIKUL et al., "Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics", J. Cell. Biol., (20120000), vol. 199, no. 3, doi:10.1083/jcb.201207033, pages 417 - 421, XP055393511

DOI:   http://dx.doi.org/10.1083/jcb.201207033
    - JIANG et al., "Allele-specific silencing of mutant MYH6 transcripts in mice suppresses hypertrophic cardiomyopathy", Science, (20130000), vol. 342, no. 6154, doi:10.1126/science.1236921, pages 111 - 114, XP055393323

DOI:   http://dx.doi.org/10.1126/science.1236921
    - MORKIN, E., "Control of cardiac myosin heavy chain gene expression", Microsc. Res. Tech., (20000000), vol. 50, pages 522 - 531
    - MIYATA et al., "Myosin heavy chain isoform expression in the failing and nonfailing human heart", Circ. Res., (20000000), vol. 86, no. 4, pages 386 - 90
    - HARADA et al., Circulation, (19990000), vol. 100, pages 2093 - 2099
    - MIYATA et al., "Myosin heavy chain isoform expression in the failing and nonfailing human heart", Circ Res., (20000303), vol. 86, no. 4, pages 386 - 90
    - JAMES et al., "Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions", Circulation, (20050000), vol. 111, no. 18, pages 2339 - 2346
    - VAN ROOJI et al., "A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance", Dev. Cell, (20090000), vol. 17, pages 662 - 673
    - LIUOLSON, "MicroRNA regulatory networks in cardiovascular development", Dev. Cell, (20100000), doi:10.1016/J.DEVCEL.2010.03.010, pages 510 - 525, XP002658553

DOI:   http://dx.doi.org/10.1016/J.DEVCEL.2010.03.010
    - MONTGOMERY et al., Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure, Circulation, American Heart Association, Inc and Scientific Sessions of the American-Heart-Association/Resuscitation Science Symposium, (20110100), vol. 124, pages 1537 - 1547
    - YEUNG et al., "Myh7b/miR-499 gene expression is transcriptionally regulated by MRFs and Eos", Nucleic Acids Res., (20120000), vol. 40, no. 15, pages 7303 - 18
    - ROSSI et al., "Two novel/ancient myosins in mammalian skeletal muscles: MYH14/7b and MYH15 are expressed in extraocular muscles and muscle spindles", J Physiol., (20100115), vol. 588, pages 353 - 64
    - BELL et al., "Uncoupling of expression of an intronic microRNA and its myosin host gene by exon skipping", Mol. Cell. Biol., vol. 30, pages 1937 - 1945
    - GERALD DORN, II, "MicroRNAs: redefining mechanisms in cardiac disease", J. Cardiovasc. Pharmacol., (20100000), vol. 56, no. 6, pages 589 - 595
    - WANG et al., Bioorganic and Medicinal Chemistry Letters, (19990000), vol. 9, pages 1147 - 1150
    - MCGUIRE et al., "In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo", J. Mol. Bio, (20040000), vol. 342, doi:10.1016/j.jmb.2004.06.029, pages 171 - 182, XP004844899

DOI:   http://dx.doi.org/10.1016/j.jmb.2004.06.029
    - MOORE et al., Circulation Research, (20120000), vol. Ill, pages 375 - 385
    - TUERKGOLD, Science, (19900000), vol. 249, pages 505 - 510
    - ELLINGTONSZOSTAK, Nature, (19900000), vol. 346, pages 818 - 822
    - FRANZ et al., Cardioscience, (19940000), vol. 5, no. 4, pages 235 - 43
    - KELLY et al., J. Cell Biol., (19950000), vol. 129, no. 2, pages 383 - 396
    - MOSS et al., Biol. Chem., (19960000), vol. 271, no. 49, pages 31688 - 31694
    - BHAVSAR et al., Genomics, (19960000), vol. 35, no. 1, pages 11 - 23
    - BARNES et al., J. Biol. Chem., (19970000), vol. 272, no. 17, pages 1 1510 - 11517
    - KIMURA et al., Dev. Growth Differ., (19970000), vol. 39, no. 3, pages 257 - 265
    - ZIOBERKRAMER, J. Bio. Chem., (19960000), vol. 271, no. 37, pages 22915 - 22
    - LAPOINTE et al., Hypertension, (19960000), vol. 27, no. 3, pages 715 - 22
    - GOPAL-SRIVASTAVA, J. Mol. Cell. Biol., (19950000), vol. 15, no. 12, pages 7081 - 7090
    - YAMAUCHI-TAKIHARA et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, no. 10, pages 3504 - 3508
    - LAPOINTE et al., J. Biol. Chem., (19880000), vol. 263, no. 19, pages 9075 - 9078
    - VAN ROOJI et al., "Control of stress-dependent cardiac growth and gene expression by a microRNA", Science, (20070000), vol. 316, no. 5824, doi:10.1126/science.1139089, pages 1035 - 1038,15701580, XP009108166

DOI:   http://dx.doi.org/10.1126/science.1139089
    - MONTGOMERY et al., "Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure", Circulation, (20110000), vol. 124, no. 14, doi:10.1161/CIRCULATIONAHA.111.030932, pages 1537 - 1547, XP002674571

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.111.030932
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.